Tyler, TX 的 大腸直腸癌 臨床試驗
8 項針對 大腸直腸癌 的研究正在 Tyler（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #70, Tyler
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
招募中3 期
- Texas Oncology - Northeast Texas, Tyler
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
招募中3 期
- UT Health East Texas HOPE Cancer Center, Tyler
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
招募中3 期
- Texas Oncology, P.A. - Tyler, Tyler
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
招募中3 期
- Clinical Study Site, Tyler
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
招募中1 期
- University of Texas at Tyler, Tyler
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
招募中1/2 期
- Texas Oncology, Tyler
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
招募中2 期
- Texas Oncology - Northeast Texas, Tyler
其他城市的 大腸直腸癌 試驗
- Houston, TX102 項研究
- New York City, NY78 項研究
- Nashville, TN69 項研究
- Boston, MA63 項研究
- Los Angeles, CA59 項研究
- Arlington, VA52 項研究
- St. Louis, MO50 項研究
- San Antonio, TX46 項研究
- Philadelphia, PA44 項研究
- Grand Rapids, MI40 項研究
- Baldwin Park, CA37 項研究
- Chicago, IL34 項研究
Tyler 的其他研究
- 非小細胞肺癌20 項研究
- 克隆氏症17 項研究
- 潰瘍性結腸炎15 項研究
- 心臟衰竭8 項研究
- 卵巢癌7 項研究
- 癌症（所有類型）7 項研究
- 頭頸部鱗狀細胞癌6 項研究
- 子宮內膜癌6 項研究
- 乳癌6 項研究
- 小細胞肺癌5 項研究
- 發炎性腸道疾病5 項研究
- 消化系統疾病5 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。